

**Complete if Known**

**(Use as many sheets as necessary)**

Application Number	10/505,313
Filing Date	August 20, 2004
First Named Inventor	Michael Bardoff
Art Unit	1649
Examiner Name	G.S. Emch
Attorney Docket Number	F2842 US S3 (C018016/0180304)

[illegible]

FOREIGN PATENT DOCUMENTS						T <sup>6</sup>
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		WO 94/17197	08-04-1994	SUZUKI et al.	abstract only	
		JP HEI 03/502455	06-06-1991			

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/505,313
		Filing Date	August 20, 2004
		First Named Inventor	Michael Bardoff
		Art Unit	1649
		Examiner Name	G.S. Emch
Sheet 2	of 2	Attorney Docket Number	F2842 US S3 (C018016/0180304)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Cheong, et al. "Affinity enhancement of bispecific antibody against two different epitopes in the same antigen," Biochemical and Biophysical Research Communications, 173:795-800 (1990).	
		Frenkel, et al. "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of $\beta$ -amyloid peptide is essential for modulation of fibrillar aggregation," Journal of Neuroimmunology, 95:136-142 (1999).	
		Frenkel, et al. "Immunization against Alzheimer's $\beta$ -amyloid plaques via EFRH phage administration," Proc. Natl. Acad. Sci., 97:11455-11459 (2000)	
		O'Nuallain, et al. "Conformational Abs Recognizing A Generic Amyloid Fibril Epitope," Proc. Natl. Acad. Sci. 99:1485-1490 (2002).	
		Solomon, et al. "Disaggregation of Alzheimer $\beta$ -amyloid by site-directed mAb," Proc. Natl. Acad. Sci., 94:4109-4112 (1997).	
		Solomon, et al. "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer $\beta$ -amyloid peptide," Proc. Natl. Acad. Sci. 93:452-455 (1996).	
		Schier, et al. "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site" J. Mol. Biol. 263:551-567 (1996).	
		Kay, et al. "An M13 Phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets" Gene 128:59-65 (1993).	
		Frenkel, et al. "N-terminal EFRH sequence of Alzheimer's $\beta$ -amyloid peptide represents the epitope of its anti-aggregating antibodies" Journal of Neuroimmunology 88: 85-90 (1998).	
		Solomon, et al. "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens" Stabilitly and Stabilization of Biocatalysts 183-188 (1998)	

Examiner Signature	/Gregory Emch/	Date Considered	04/24/2009
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./